As major restaurant chains rethink portion sizes and menu formats, smaller and more snackable items are getting more attention across the fast-food business. Burger King is now testing Whopper Bites, a new take on its flagship burger, as part of that broader shift. The test adds Burger King to a growing list of chains adjusting menus while executives across the industry discuss changing eating habits tied to GLP-1 drugs such as Ozempic.
Burger King starts a limited Whopper Bites test
Burger King has started testing Whopper Bites, the company confirmed, adding a smaller-format item tied to its best-known burger brand. The company has not publicly released a nationwide launch plan, and the test is limited rather than systemwide. Burger King has also not confirmed a total store count for the trial.
The test matters because the Whopper is Burger King’s signature sandwich, sold for decades as a full-size burger. By using the Whopper name on a bite-size product, the chain is signaling that smaller portions are worth testing under one of its biggest menu brands. The company has not released pricing, calories, or a permanent menu date.
Restaurant companies have been increasingly vocal since 2023 and 2024 about watching demand patterns around GLP-1 medications. Burger King’s move places it directly inside that conversation, even though the company has only confirmed a test and not a broader strategy rollout.
What is known so far about where the test is happening
Burger King has confirmed the Whopper Bites test, but it has not released a full list of locations where the item is available. That means customers in any specific state or city may not know whether their nearest restaurant is included unless the local store is participating. No comprehensive state-by-state count has been made public.
What is confirmed is that the product is in test mode and not available across all U.S. Burger King restaurants. Burger King has more than 6,000 U.S. locations, but the company has not said how many are part of this trial. It also has not stated how long the market test will run.
For diners, that means availability may vary by restaurant and by market during the test period. It also means menu boards, app listings, and local promotions may not match from one Burger King location to another while the company evaluates the item.
Why fast-food chains are looking harder at smaller portions
The broader context is the rise of GLP-1 drugs, including Ozempic, which have been widely discussed by restaurant executives and industry analysts since 2023. Those drugs are associated with lower appetite for some users, and that has pushed food companies to study whether smaller portions, snack items, and flexible menu formats could better match changing habits.
Burger King has not said that Whopper Bites were created solely because of Ozempic or any single medication trend. What is clear is that the test arrives during a period when chains are weighing traffic, check size, and menu mix more carefully. In that environment, a smaller Whopper-branded item gives Burger King another format to measure.
For customers, the immediate takeaway is simple: this is still a test, not a national launch. Burger King has only confirmed that Whopper Bites are being tried, and more details on pricing, participating markets, and any wider expansion have not yet been released. The next update is likely to come if the company decides the test should continue or expand.
